ARTICLE | Clinical News
sCR1: Began a Phase I trial
October 3, 1994 7:00 AM UTC
T Cell Sciences Inc. (TCEL), Cambridge, Mass. Product: sCR1 soluble complement receptor 1, which inhibits complement activation, reducing mediators of inflammation Indication: Acute lung injury Stat...